Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test

Quest Diagnostics  (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M™ Integrated Cycler. 

The test, from the company's Focus Diagnostics business, is intended to aid in the diagnosis of Clostridium difficile-associated disease, one of the most common and dangerous acquired infections in healthcare settings. It uses a proprietary technique to eliminate the time consuming nucleic-acid sample extraction process required by many other molecular tests, for potentially faster results reporting for hospitals and clinical laboratories.

Simplexa tests, running on the 3M™ Integrated Cycler, employ real-time polymerase chain reaction (RT-PCR) to qualitatively detect viruses, bacteria and other analytes. The Simplexa C. difficile Universal Direct test is performed on liquid or unformed human stool samples and detects the toxin B gene (tcdB) of C. difficile, including NAP1. The test uses a proprietary chemistry that eliminates the need for nucleic-acid extraction. Using the Simplexa test, hospital and other labs may complete the entire testing process in about an hour.

C. difficile-associated disease is a common and sometimes fatal healthcare-associated infection that causes diarrhea and other intestinal problems. As many as 14,000 people die of C. difficile-associated disease in the United States each year, according to the U.S. Centers for Disease Control and Prevention. 

"Detecting and containing C. difficile associated disease is one of the greatest clinical challenges in today's healthcare environment," said Jay M. Lieberman, M.D., medical director, infectious disease, for Quest Diagnostics and Focus Diagnostics.  "Fast, reliable PCR tests that are highly specific and sensitive in the detection of the tcdB gene, a toxin-B producing gene of C. difficile, are essential for identifying and treating this infection as well as containing its spread."

With the FDA clearance, the Simplexa C. difficile Universal Direct Test on the 3M Integrated Cycler is immediately available in the United States. Focus Diagnostics launched the test in Europe during the second quarter of 2011.

Source:

Quest Diagnostics

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Quest Diagnostics. (2019, June 19). Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test. News-Medical. Retrieved on November 24, 2020 from https://www.news-medical.net/news/20120412/Quest-Diagnostics-receives-FDA-clearance-for-Simplexa-C-difficile-Universal-Direct-test.aspx.

  • MLA

    Quest Diagnostics. "Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test". News-Medical. 24 November 2020. <https://www.news-medical.net/news/20120412/Quest-Diagnostics-receives-FDA-clearance-for-Simplexa-C-difficile-Universal-Direct-test.aspx>.

  • Chicago

    Quest Diagnostics. "Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test". News-Medical. https://www.news-medical.net/news/20120412/Quest-Diagnostics-receives-FDA-clearance-for-Simplexa-C-difficile-Universal-Direct-test.aspx. (accessed November 24, 2020).

  • Harvard

    Quest Diagnostics. 2019. Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test. News-Medical, viewed 24 November 2020, https://www.news-medical.net/news/20120412/Quest-Diagnostics-receives-FDA-clearance-for-Simplexa-C-difficile-Universal-Direct-test.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
IBM, Quest Diagnostics launch new genomic tumor sequencing service to help advance precision medicine